Lung transplant rejection - Pipeline Insight, 2021
This report can be delivered to the clients within 48 hours
DelveInsight’s, “Lung transplant rejection - Pipeline Insight, 2021,” report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Lung transplant rejection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Lung transplant rejection: Overview
Lung transplant rejection is a common complication after a single or double lung transplant, and it can progress rapidly or subtly. Early diagnosis and management are essential to decrease morbidity and mortality. It is best managed by an interprofessional team approach. Communication and coordination between the patient, the primary clinician, the pulmonologist, and the transplant surgeon in regard to posttransplant testing and follow-up are essential for prevention. Acute lung transplant rejection may increase the risk of a recurrence of acute rejections and the development of bronchiolitis obliterans syndrome.
'Lung transplant rejection - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Lung transplant rejection pipeline landscape is provided which includes the disease overview and Lung transplant rejection treatment guidelines. The assessment part of the report embraces, in depth Lung transplant rejection commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Lung transplant rejection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Lung transplant rejection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Lung transplant rejection Emerging Drugs
Further product details are provided in the report.
Lung transplant rejection: Therapeutic Assessment
This segment of the report provides insights about the different Lung transplant rejection drugs segregated based on following parameters that define the scope of the report, such as:
Lung transplant rejection: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Lung transplant rejection therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lung transplant rejection drugs.
Lung transplant rejection Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Lung transplant rejection - Pipeline Insight, 2021,” report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Lung transplant rejection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Lung transplant rejection: Overview
Lung transplant rejection is a common complication after a single or double lung transplant, and it can progress rapidly or subtly. Early diagnosis and management are essential to decrease morbidity and mortality. It is best managed by an interprofessional team approach. Communication and coordination between the patient, the primary clinician, the pulmonologist, and the transplant surgeon in regard to posttransplant testing and follow-up are essential for prevention. Acute lung transplant rejection may increase the risk of a recurrence of acute rejections and the development of bronchiolitis obliterans syndrome.
'Lung transplant rejection - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Lung transplant rejection pipeline landscape is provided which includes the disease overview and Lung transplant rejection treatment guidelines. The assessment part of the report embraces, in depth Lung transplant rejection commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Lung transplant rejection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Lung transplant rejection R&D. The therapies under development are focused on novel approaches to treat/improve Lung transplant rejection.
This segment of the Lung transplant rejection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Lung transplant rejection Emerging Drugs
- TFF TAC-LAC: TFF PHARMACEUTICALS
- Belatacept: Bristol-Myers Squibb
Further product details are provided in the report.
Lung transplant rejection: Therapeutic Assessment
This segment of the report provides insights about the different Lung transplant rejection drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Lung transplant rejection
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Lung transplant rejection: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Lung transplant rejection therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lung transplant rejection drugs.
Lung transplant rejection Report Insights
- Lung transplant rejection Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Lung transplant rejection drugs?
- How many Lung transplant rejection drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Lung transplant rejection?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Lung transplant rejection therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Lung transplant rejection and their status?
- What are the key designations that have been granted to the emerging drugs?
- TFF Pharmaceuticals
- Bristol-Myers Squibb
- Zambon SpA
- CSL Behring
- MimeTech
- Roche
- Corline Biomedical
- Kamada
- Quark Pharmaceuticals
- Radikal Therapeutics
- TFF TAC-LAC
- Belatacept
- Liposomal Cyclosporine A
- Hizentra
- Udonitrectag
- Pirfenidone
- Renaparin
- Alpha-1 antitrypsin
- QP LI1
Introduction
Executive Summary
Lung transplant rejection: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Lung transplant rejection – DelveInsight’s Analytical Perspective
Mid Stage Products (Phase II)
Comparative Analysis
Belatacept: Bristol-Myers Squibb
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Early Stage Products (Phase I)
Comparative Analysis
TFF TAC-LAC: TFF PHARMACEUTICALS
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Preclinical and Discovery Stage Products
Comparative Analysis
Udonitrectag: MimeTech
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Inactive Products
Comparative Analysis
Lung transplant rejection Key Companies
Lung transplant rejection Key Products
Lung transplant rejection- Unmet Needs
Lung transplant rejection- Market Drivers and Barriers
Lung transplant rejection- Future Perspectives and Conclusion
Lung transplant rejection Analyst Views
Lung transplant rejection Key Companies
Appendix
Executive Summary
Lung transplant rejection: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Lung transplant rejection – DelveInsight’s Analytical Perspective
Mid Stage Products (Phase II)
Comparative Analysis
Belatacept: Bristol-Myers Squibb
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Early Stage Products (Phase I)
Comparative Analysis
TFF TAC-LAC: TFF PHARMACEUTICALS
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Preclinical and Discovery Stage Products
Comparative Analysis
Udonitrectag: MimeTech
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Inactive Products
Comparative Analysis
Lung transplant rejection Key Companies
Lung transplant rejection Key Products
Lung transplant rejection- Unmet Needs
Lung transplant rejection- Market Drivers and Barriers
Lung transplant rejection- Future Perspectives and Conclusion
Lung transplant rejection Analyst Views
Lung transplant rejection Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Lung transplant rejection
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Lung transplant rejection
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Lung transplant rejection
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Lung transplant rejection
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
